Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This registry collects detailed information about children diagnosed with cancer who are treated in pediatric oncology units affiliated with the French African Oncology Group in French-speaking Africa. Its goal is to gather data on patient numbers, cancer stage, treatments received, and outcomes to support better planning and delivery of pediatric oncology care in the region. The registry aims to provide valuable insights for local and national health authorities to improve pediatric cancer programs. Children and adolescents under 18 years old who present at participating pediatric oncology units and have any type of cancer are included in this observational registry. Data collected includes demographic information, socioeconomic status, clinical details, treatment status, vital status, treatment abandonment, and loss to follow-up. The information is entered online using the REDCap system and securely stored by the IT department at Gustave ROUSSY in Paris. Participants information is gathered continuously during their treatment and follow-up at the hospital units. The main measures tracked include the number of children suspected of having cancer within 12-month periods, their vital status, illness status, and treatment status. This ongoing data collection helps monitor outcomes and supports healthcare planning. Participation involves no experimental treatment and is focused on data recording and observation over time.
Actively Recruiting
Healthy Volunteer
Multidrug-resistant tuberculosis MDR-TB is a major health challenge in Central Africa. Researchers are studying the molecular epidemiology and genetic characteristics of MDR-TB strains to better understand how the disease spreads and evolves. This study focuses on mutations linked to resistance against important drugs like bedaquiline and quinolones, which could affect new treatment regimens involving Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin. The research also examines the role of TB lineage in infection outcomes and transmission patterns. This observational study involves screening GeneXpert positive TB patients aged 9 and older who can provide sputum samples. Participants already enrolled in a related tuberculosis epidemiology study may also be included without additional consent. The study collects and shares data on the genetic makeup of TB strains, focusing on identifying resistance mutations and transmission links within and between countries. Participants provide sputum samples for laboratory analysis to characterize drug resistance mutations and detect transmission chains. The primary outcomes measured over six months include the proportion of drug-resistant strains with known resistance mutations, the proportion with new mutations among unexplained resistance cases, and the proportion of cases showing transmission connections. The study aims to improve understanding of MDR-TB spread and resistance in the region, with participation lasting up to the study completion date in December 2026.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a combination of anti-malarial drugs in children aged 2 to under 12 years with uncomplicated Plasmodium falciparum malaria. This phase 2 platform study compares a single oral dose of up to three anti-malarial agents given together to the standard treatment known as Coartem. The study aims to better understand how these treatments work and their safety profiles in this young population. Participants are randomly assigned to one of two groups one receiving an oral combination of KLU156 with KAE609 alongside a light meal, and the other receiving the standard of care, Artemether plus lumefantrine, given orally according to the usual guidelines. This open-label, two-arm study monitors each treatment groups response to therapy. Throughout the study, participants undergo evaluations including parasite clearance times and blood tests to measure drug levels over the first week, with the main outcome assessed on day 29 using PCR to confirm clinical and parasitological response. Safety and tolerability are also closely monitored, and the total duration of participation extends up to 29 days after treatment initiation to assess treatment outcomes comprehensively.
Actively Recruiting
Researchers are evaluating how well different anti-malarial drugs work and how safe they are for treating uncomplicated Plasmodium falciparum malaria in adults, adolescents, and children. This study focuses on the parasite-killing effects and potential cure rates of these drugs when given alone or combined with others. It also looks at how the drugs are processed by the body to help decide doses for future studies. Participants will receive one of several treatments, including varying doses of the oral drug INE963, combinations of oral KAE609 Cipargamin with INE963 or KLU156, or the standard of care drug Coartem. The study has multiple parts with patients allocated randomly to different treatment groups. Dosing levels and combinations are tested to compare how effectively they clear the malaria parasite. During the study, participants will have their parasite levels monitored up to 7 days and clinical response assessed by day 29. Blood samples will be taken by day 22 to study drug levels and how the body absorbs and clears the medicines. Safety is monitored through reports of side effects until day 43. The total participation lasts through these assessments to understand treatment impact and tolerability.